Mitochondria, Not Mutations: The Hidden Engine Behind Cancer, and How Somatid Technology Supports Cellular Balance

For decades, conventional medicine has framed cancer as a genetic disease, a collection of random mutations that spiral out of control.

But new research published in Nature Cancer offers a profound shift in understanding: cancer may begin in the mitochondria, not the genes.

Researchers found that cancer cells can transfer their mitochondria into nearby fibroblasts, converting them into tumor-supporting cells. These fibroblasts didn’t acquire new mutations; instead, their metabolic and energetic profiles were reprogrammed.

The key player: MIRO2, a protein that enables mitochondrial transfer between cells. When researchers blocked MIRO2, the process stopped, and tumor growth slowed dramatically.

This supports the metabolic theory of cancer, long championed by biochemist Thomas Seyfried, who proposed that defective energy metabolism, not DNA damage, is the true driver of disease.

If mitochondria lose their electrical charge and can’t maintain energy flow, the entire cell ecosystem suffers.

That’s where Somatid Ceramic Technology offers a new perspective.
Somatids, the intelligent micro-particles embedded within QELBY® ceramic balls and Quantum Textiles, help maintain the body’s electrical potential by promoting structured water formation and steady electron availability.

This creates a more coherent, energetically balanced environment for mitochondrial function to thrive.

While QELBY® products are not medical devices, they’re designed to help your body maintain its natural bio-energetic harmony, supporting hydration, energy, and recovery at the cellular level.

Because when your cells are charged and coherent, your biology can do what it was meant to do: restore, repair, and regenerate.

Learn about Somatids Science